Kornimate/medical-research-clean huggingface dataset:
exploring buckwheat's glucose lowering potential

Conditions: Type 2 Diabetes

Summary: bioactive components in buckwheat enhance insulin sensitivity in type 2 diabetes by improving glucose uptake and utilization through a unique mechanism that operates independent of insulin.

this is a single site, double-blind, randomized, controlled study designed to explore buckwheat's glucose lowering effects in healthy volunteers and volunteers with type 2 diabetes. a total of 24 volunteers consisting of 12 volunteers (healthy and diabetic) per group for both the acute and chronic phases of testing will be recruited through advertisement from the local community. in the acute testing phase, volunteers (healthy and diabetic) will be asked to attend 4 visits one week apart for the duration of 3 hours per visit. a fasting blood sample will be collected at each visit. at each visit, all volunteers will consume in random order 1 of the following 4 products: i) crackers containing buckwheat; ii) crackers without buckwheat); iii) 50 mls of oral solution containing glucose; or iv) 50 mls of oral solution containing the sugar substitute splenda. the crackers will contain equal amounts of available carbohydrates. blood sampling will occur at 15, 30, 45, 60 minutes, and then every 60 minutes for the remainder of the visit. sampling (pre and post product consumption) will measure insulin, glucose, and various incretins. open venous access will be secured after the first sample has been obtained to minimize the number of needle pricks. total amount of blood obtained will not exceed 30 mls per visit. in the chronic testing phase, volunteers (healthy and diabetic) will receive the crackers containing buckwheat for consumption each day for 7 days. prior to food consumption, a fasting blood sample will be obtained each day and a urine sample will be collected on days 1, 3, and 7 to assess bioavailability of buckwheat compounds (concentrations in blood and urine), insulin and glucose. sampling for a lipid profile (total cholesterol, ldl-cholesterol, hdl-cholesterol and triglycerides), liver (alt), kidney (creatinine), adipose function (adipokines), various incretins, as well as inflammatory status (various cytokines) will be done on day 1 and day 7. total amount of blood obtained will not exceed 30 mls per visit.

Eligibility criteria:
inclusion criteria: * aged 18 to 70 years * normal glycated hemoglobin (\<6% healthy, \<7.5% diabetic) * absence of chronic conditions (except type 2 diabetes) * must be able to read and sign consent * must be able to comply with protocol requirements exclusion criteria: * allergies to eggs, buckwheat, rice flour, or sugar substitutes (splenda) * acute or chronic conditions (except type 2 diabetes) * blood glucose \>10mmol/l at beginning of test session * medications that affect glycemic control

Keywords: functional food study
simvastatin in colorectal surgery

Conditions: Intestinal Neoplasm; Perioperative Care

Summary: statins (hmg-coa reductase inhibitors) are a widely used class of cholesterol-lowering drugs that have an established role in the medical management of cardiovascular disease. their benefits have also been shown in the surgical setting with decreased cardiovascular complications and lower perioperative mortality following cardiac and vascular surgery. there is now considerable evidence showing statins have useful pleiotropic properties that extend beyond cholesterol lowering, including anti-inflammatory, anti-oxidant, immunomodulatory and fibrinolytic effects. growing evidence suggests these effects may be useful in attenuating the proinflammatory and metabolic stress response to surgery and the benefit of statins may extend to other surgical settings such as abdominal surgery. laboratory studies demonstrate the surgically-relevant benefits of statins and show they decrease peritoneal inflammation, reduce the severity of intestinal ischaemia-reperfusion injury, improve survival in models of abdominal sepsis, decrease the formation of postoperative intraperitoneal adhesions and improve the healing of colonic anastomoses. retrospective clinical studies show statins improve outcomes in sepsis, reduce the postoperative systemic inflammatory response syndrome (sirs) and are associated with decreased rates of surgical wound infections and postoperative respiratory complications following various non-cardiac general surgical procedures. however, no prospective studies have specifically evaluated the perioperative use of statins in abdominal surgery. using colorectal surgery as a model for major abdominal surgery, the investigators will conduct a randomised controlled trial evaluating the effect of perioperative statin use on postoperative morbidity, local and systemic inflammatory response, and functional recovery after surgery.


Eligibility criteria:
inclusion criteria: * consecutive consenting patients undergoing elective colectomy, rectal resection, and reversal of hartmann's procedure at middlemore hospital, manukau surgery centre, auckland city hospital, and north shore hospital. exclusion criteria: * acute presentation * already taking statins or other lipid-lowering medication * known adverse reaction to statins * hepatic dysfunction * moderate to severe renal dysfunction * previous history of rhabdomyolysis * on contraindicated medication * pregnancy * breastfeeding * patient choice.

Keywords: statin colon colorectal intestinal neoplasms eras perioperative care
to study generic tacrolimus ointment, 0.1% in the treatment of moderate to severe atopic dermatitis (inflammation of skin: itchy, red, swollen, and cracked skin)

Conditions: Atopic Dermatitis

Summary: this is a randomized, double-blind, placebo-controlled, parallel-group, multiple-site study to evaluate the therapeutic equivalence of a generic tacrolimus ointment, 0.1% (glenmark pharmaceuticals, ltd) to the marketed product protopic® (tacrolimus) ointment, 0.1% (astellas pharma us, inc.) in the treatment of moderate to severe atopic dermatitis (ad).


Eligibility criteria:
key inclusion criteria: 1. non-immunocompromised male or non-pregnant, non-lactating female, 18 years of age or older with a clinical diagnosis of moderate to severe ad. 2. have confirmed diagnosis of atopic dermatitis for at least 3 months using the diagnostic features as described by hanifin and rajka 3. have an iga score of 3 (moderate) or 4 (severe). 4. have an affected body surface area (bsa) of at least 20% at baseline. 5. treated with a bland emollient for at least 7 days. key exclusion criteria: 1. active cutaneous bacterial or viral infection in any treatment area at baseline. 2. sunburn, extensive scarring, or pigmented lesion(s) in any treatment area at baseline. 3. history of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, or ichthyosis. 4. history or presence of netherton's syndrome, immunological deficiencies or diseases, hiv, diabetes, malignancy, serious active or recurrent infection, clinically significant severe renal insufficiency or severe hepatic disorders. 5. known allergy or hypersensitivity to tacrolimus or any other component of the study products.
covid-19 vaccine effectiveness in healthcare personnel in clalit health services in israel (covehpi)

Conditions: Covid19; Corona Virus Infection; Vaccine Effectiveness

Summary: although clinical trials for approved covid-19 vaccines demonstrated efficacy of the vaccine in preventing symptomatic infection, many questions about vaccine effectiveness, such as the effectiveness of covid-19 vaccine in preventing asymptomatic infection, a surrogate for transmission, and duration of protection, can only be evaluated in real-world trials. the objective of the study is to evaluate covid-19 vaccine effectiveness (pfizer vaccine, and, if available, moderna vaccine) in preventing infection in healthcare personnel in israel. hcp who are clalit members and working in soroka, beilinson, meir, haemek, kaplan and schneider hospitals, 18 years or older, and eligible to get covid-19 vaccine according to ministry of health guidelines, will be recruited, regardless of their intention to get the covid-19 vaccine. a baseline serology sample and respiratory sample will be collected. participants will be asked to provide a respiratory sample weekly for 3 months, and then monthly for the remainder of the study. participants will also have blood drawn at 1 month, 3 months, 6 months, 9 months and 12 months. respiratory samples will be tested for sars-cov-2 by rt-pcr; serology will be tested for sars-cov-2 antibodies. the study will last for 12 months. for each participant, data will be extracted from the electronic medical record for the period of the study and retrospectively from 2010.


Eligibility criteria:
inclusion criteria: - any hcp at any of the participating hospitals who is * a member of clalit health services * is eligible to get the covid-19 vaccine * did not receive the first dose of covid-19 vaccine more than 21 days prior to the enrollment date exclusion criteria: - employees at any of the participating hospitals will be excluded if they are: * not a member of clalit health services; or * not eligible to get the covid-19 vaccine according to the ministry of health guidelines; or * less than 18 years of age * received first dose of covid-19 vaccine more than 21 days prior to date of enrollment
hpi (hypotension prediction index) care trial

Conditions: Cardiopulmonary Bypass Surgery

Summary: a prospective single-center randomized controlled trial to determine if guided hemodynamic management with the acumen hpi technology in the or and icu can reduce the mean duration of hypotension in cardiac surgery patients requiring cardiopulmonary bypass.


Eligibility criteria:
inclusion criteria: 1. subjects who are at least 18 years of age 2. subjects who have signed the informed consent form 3. subjects with planned pressure monitoring with an arterial line 4. subjects with planned sternotomy 5. subjects with planned general anesthesia 6. subjects who have asa physical status ≤ 4 7. subjects with planned cerebral oximetry monitoring 8. subjects with planned overnight hospitalization 9. subjects with planned cardiopulmonary bypass (cpb) "on-pump" surgery exclusion criteria: 1. subjects with a physical site area too limited for proper sensor placement 2. subjects with contraindications for arterial line placement; 3. subjects participating in another (interventional) study 4. subjects in whom an intraoperative map target will be \< 65 mmhg 5. subjects with pre-op or pre-pump or post-pump lvef \< 15% 6. subjects requiring heart transplant 7. subjects with pre-existing circulatory support devices or planned circulatory support devices post-bypass 8. subjects requiring emergency surgery 9. subjects with known or identified severe pah (defined as pulmonary systolic pressure\> 70mmhg or mean pressures \> 55mmhg) as determined by a pre-operative echo or intraoperative swan-ganz 10. subjects with cardiovascular instability in the operating room necessitating the need to go back on bypass for a subsequent run

Keywords: cardiopulmonary bypass
exploratory pk and imaging study of psma-targeted trillium compounds and pti-122 in metastatic prostate cancer

Conditions: Prostate Cancer

Summary: exploratory study in adult males with metastatic prostate cancer intended to characterize the pharmacokinetics and biodistribution of psma-targeted \[in-111\]-labeled trillium compounds with and without the cytoprotective agent pti-122. up to 36 eligible subjects will be enrolled. additional subjects may be enrolled if there is insufficient data for evaluation, for example if the original study subjects do not complete required imaging studies for reasons unrelated to adverse events. up to four psma-targeted \[in-111\]-labeled trillium compounds will be evaluated. each compound will be evaluated first without the cytoprotective agent, pti-122, then the \[in-111\]-labeled trillium compound may be co-administered with pti-122.


Eligibility criteria:
inclusion criteria: * adult males with metastatic prostate cancer * ecog performance score 0-2 * stable androgen deprivation or other hormone therapy (30 days) or therapy planned but not yet initiated * psma pet scan between 3 and 28 days prior to radiotracer injection with at least 2 psma positive lesions and either: 1. one soft tissue lesion measuring ≥ 15 mm in the longest diameter with suvmax lesion ≥ suvmean normal liver, or 2. two bone lesions measuring ≥ 15 mm in the longest diameter with suvmax lesion ≥ 2 x suvmax normal liver * able to understand and adhere to study requirements, and voluntarily give informed consent exclusion criteria: * no other malignancy undergoing treatment * no psma-targeted therapy ongoing * inability or unwillingness to undergo spect/ct imaging * serum creatinine \> 1.5 mg/dl or creatinine clearance ≤50 ml/min by cockcroft-gault estimation * concurrent participation in the active treatment phase of another clinical trial of investigational medicinal product(s) * significant intercurrent illness, treatment-related toxicity, or psychiatric illness/social situation that could place the subject at undue risk during study participation, significantly alter study outcomes, or affect subject compliance with study requirements for dosing and evaluation, as determined by the investigator
research development（rd）13-02 chimeric antigen receptor(car) -t cell injection for patients with r/r cluster of differentiation 7（cd7）+ t-acute lymphoblastic leukemia(all)/t-lymphoblastic lymphoma(lbl) /acute myelogenous leukemia(aml)

Conditions: Neoplasms; Hematologic Neoplasms; Hematologic Diseases

Summary: this is a single-arm, open-label, single-center, phase i study. the primary objective is to evaluate the safety of cd7 car-t therapy for patients with cd7-positive relapsed or refractory t-all/lbl/aml, and to evaluate the pharmacokinetics of cd7 car-t in patients.


Eligibility criteria:
inclusion criteria: 1. age 3-70 2. diagnosis of r/r t-all/lbl/aml. 3. cd7 positive expression 4. bone marrow lymphoblasts ≥5% by morphologic evaluation at screening 5. creatinine clearance (as estimated by cockcroft gault) ≥ 60 ml/min, serum alanine aminotransferase(alt)/aspartate aminotransferase(ast) \< 3×upper limit of normal, total bilirubin \< 1.5×upper limit of normal or ≤1.5mg/dl 6. left ventricular ejection fraction ≥ 50% . 7. baseline oxygen saturation ≥ 92% on room air. 8. eastern cooperative oncology group (ecog) performance status of 0 to 2. 9. the estimated survival time is more than 3 months. 10. subjects or their legal guardians volunteer to participate in the study and sign the informed consent. exclusion criteria: 1. for aml patients, there are acute promyelocytic leukemia (apl) and abelson murine leukemia viral oncogene homolog(bcr-abl) positive leukemia (chronic myeloid leukemia with acute(cml)-bc). 2. subjects with concomitant genetic syndromes associated with bone marrow failure states. 3. subjects with some cardiac conditions will be excluded. 4. history of traumatic brain injury, consciousness disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic disease, which might compromise the ability of the subject to compliance with the obligations under the protocol. 5. history of malignancy other than non-melanoma skin cancer or carcinoma. 6. primary immune deficiency. 7. presence of uncontrolled infections. 8. subjects with some anticancer therapy before car-t infusion will be excluded. 9. active uncontrolled acute infections. 10. known history of infection with human immunodeficiency virus (hiv); active or latent hepatitis b, hepatitis c and syphilis. 11. subjects who are receiving systemic steroid therapy prior to screening. 12. subjects with acute graft-versus-host disease (gvhd) 13. having received live/attenuated vaccine within 4 weeks prior to screening. 14. history of allergy to any component of the cell therapy product. 15. pregnant or breastfeeding women 16. any other issue which, in the opinion of the investigator, would make the subjects ineligible for the study.
multicenter rehabilitation study in acute stroke

Conditions: Stroke

Summary: the purpose of the first part of this study is to understand plastic brain mechanisms associated with successful gait-oriented stroke rehabilitation. patients are randomized to receive intensive in-patient multiprofessional rehabilitation at different time points. one group will receive rehabilitation immediately after an acute care at the neurological clinic (8 days) and one group 5 weeks after the insult. patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy. in addition to selected parameters measuring brain plasticity, detailed assessments of functional abilities including motor ability and quality of life will be performed. a novel tool, mr-image navigated transcranial magnetic stimulation (tms) is utilized in assessing cortical excitability in relation to stroke, time, rehabilitation, and recovery.


Eligibility criteria:
inclusion criteria: * first supratentorial stroke or no significant disturbance from an earlier stroke (modified ranking scale, mrs 0-2) * time since onset of stroke no more than 10 days * functional ambulatory category (fac) 0-3 * voluntary movement in the leg of the affected side * barthel index (bi) 25-75 points- no unstable cardiovascular disease * body mass index (bmi) \<32 * no severe malposition of joints * no severe cognitive or communicative disorders * no other health-related or social barriers to participate intensive rehabilitation exclusion criteria: * ich, or mrs \>2 * time since onset of stroke more than 10 days * fac \>3 * no voluntary movement in the leg of the affected side * bi \ 75 * severe malposition of joints * severe cognitive or communicative disorders

Keywords: stroke rehabilitation gait timing transcranial magnetic stimulation
minimal extracorporeal circuits (mecc) in cardiac surgery procedures

Conditions: Postoperative Bloodloss

Summary: the standard heart-lung machine is a major trigger of systemic inflammatory reactions, hemodilution, coagulopathy or organ failure. the strict reduction of blood-artificial surface and blood-air contact might represent meaningful improvements of the extracorporeal technology with respect to organ preservation. the aim of this study is the evaluation of potential differences between a minimal extracorporeal circuit (mecc) and a conventional cardiopulmonary bypass (mops) system.


Eligibility criteria:
inclusion criteria: * extracorporeal circulation * age \> 18 years old

Keywords: minimizing cardiopulmonary bypass mecc damage organ failure
coreg mr versus toprol-xl on reduction of microalbuminuria in patients with hypertension and microalbuminuria

Conditions: Heart Failure, Congestive and Microalbuminuria

Summary: this study was designed to determine whether coreg mr is more effective than toprol-xl in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria.


Eligibility criteria:
inclusion criteria: * documented history of hypertension. * must have been taking an ace (angiotensin converting enzyme) inhibitor either alone or as part of an antihypertensive regimen for at least 8 weeks. * persistent microalbuminuria. exclusion criteria: * history of heart attack, stroke, congestive heart failure, arrhythmia, type 1 or uncontrolled type 2 diabetes mellitus, liver or renal disease. * has been taking any non-ocular beta-blockers for any indication within three months prior to pre-screening.

Keywords: hypertension urine albumin:creatinine ratio microalbuminuria
the effectiveness of prolotherapy (%5 dextros) in the treatment of patients with chondromalacia patella

Conditions: Chondromalacia Patellae

Summary: dextrose prolotherapy is a form of treatment in which hypertonic dextrose solution is used as a stimulant solution and regeneration is increased by stimulating the body's natural healing mechanisms after injection. the aim of this study is to compare the dextrose prolotherapy applied with home exercise program and saline injections as a control group in patients who applied to our clinic with knee pain and diagnosed with chondromalacia patella, and to investigate the effectiveness of dextrose and saline on the job to determine the superiority of the injections to each other.

the study was designed as prospective, randomized, controlled trial. 48 people who met the inclusion criteria were randomized into two groups of 24 people. the first group will be designated as dextrose prolotherapy group and dextrose prolotherapy and exercise program will be applied to these patients. patients in the second group will be designated as the serum physiological group, and injections with saline and home exercise program will be applied in accordance with the prolotherapy protocol.participants were evaluated with visual analogue scale (vas), patello femoral pain severity scale (pfpss), kuala patellofemoral scoring system (kpss) and short form 36 (sf-36).knee cartilage thickness measurements and the presence of suprapatellar effusion of the participants whose evaluations are completed will be evaluated bilaterally by ultrasonography and the findings will be recorded.

Eligibility criteria:
inclusion criteria: * female / male aged\> 18 years * diagnosis of chondromalacia patella after physical examination and imaging (direct radiography, mri) * those whose symptoms persist\> 3 months * does not have a disease that will prevent him from exercising * participation in the study voluntarily and regularly exclusion criteria: * pregnant patients * history of previous knee surgery * having received physical therapy from the knee area in the last 3 months * drug allergy * previous prolotherapy or any injection up to 3 months ago * those with pain reflected from waist or hip * patients with neuropathic pain * tumor, infectious, psychiatric illness, history of bleeding diathesis * having a trauma history in the last 6 months * those with systemic diseases such as diabetes, hepatitis, coagulopathy * those with cerebrovascular event disease in which bleeding continues actively * those who received nsaid treatment within the last week * patients with a bmi\> 40 * finding leg length difference

Keywords: prolotherapy knee pain ultrasound exercise